e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade
Samuel Bostock, Karen Sheares, John Cannon, Dolores Taboada, Joanna Pepke-Zaba, Mark Toshner
Source:
Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017
Journal Issue:
December
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Samuel Bostock, Karen Sheares, John Cannon, Dolores Taboada, Joanna Pepke-Zaba, Mark Toshner. The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Investigation of the effects of neuromuscular electrical stimulation in patients with pulmonary arterial hypertension
Source: International Congress 2018 – Acutely hospitalised patients: physiotherapy interventions and assessment methods
Year: 2018
SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Increased renin-angiotensin-aldosteron system activity in lungs of patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Year: 2011
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity
Source: Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019
Year: 2020
Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses
Source: Eur Respir J 2013; 42: 1575-1585
Year: 2013
CFTR involvement in the pathogenesis of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Safety of switching from different prostanoids in the treatment of idiopathic pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
The influence of fractional pulse pressure on the outcome of pulmonary thromboendarterectomy
Source: Eur Respir J 2001; 17: 653-659
Year: 2001
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept